Fate Therapeutics (FATE) Stock Price, News & Analysis

Company Overview

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cellular immunotherapies for cancer and autoimmune diseases. The company uses induced pluripotent stem cell (iPSC) technology to create standardized, potentially off-the-shelf immune cell products, including natural killer (NK) cells and T cells.

Its research and development activities include iPSC-derived cell therapies engineered to recognize and attack cancer cells. Fate’s pipeline has included candidates such as FT819, an iPSC-derived, CD19-targeted CAR T-cell therapy, along with other investigational NK-cell and T-cell programs. These products are designed to provide consistent manufacturing, scalable production and potentially broader access than individualized cell therapies.

Founded in 2007 and headquartered in San Diego, California, Fate Therapeutics conducts research and clinical development primarily in the United States while pursuing therapies intended for patients internationally. The company’s programs have been evaluated in clinical studies involving hematologic malignancies and other serious diseases. Scott Wolchko has served as the company’s president and chief executive officer.

Key Stats

• Today's Range: $1.81 to $1.95
• 50-Day Range: $1.79 to $2.58
• 52-Week Range: $0.95 to $3.23
• Volume: 1.86 million shs
• Average Volume: 1.17 million shs
• Market Capitalization: $219.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.80
• Consensus Rating: Moderate Buy

Fate Therapeutics Stock Analysis - MarketRank™

Fate Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 255th out of 886 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Fate Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Fate Therapeutics has a consensus price target of $5.80, representing about 216.1% upside from its current price of $1.84.

Amount of Analyst Coverage

Fate Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Fate Therapeutics are expected to grow in the coming year, from ($1.03) to ($1.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fate Therapeutics is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fate Therapeutics is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Fate Therapeutics has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.30% of the float of Fate Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Fate Therapeutics has a short interest ratio ("days to cover") of 8.73.

Change versus previous month

Short interest in Fate Therapeutics has recently decreased by 1.31%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fate Therapeutics does not currently pay a dividend.

Dividend Growth

Fate Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.48

News Sentiment

Fate Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Fate Therapeutics this week, compared to 3 articles on an average week.

Search Interest

5 people have searched for FATE on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

MarketBeat Follows

3 people have added Fate Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Fate Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.74% of the stock of Fate Therapeutics is held by insiders.

Percentage Held by Institutions

97.54% of the stock of Fate Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/05/2026
• Today: 11/07/2026
• Jefferies Global Healthcare Conference: 11/15/2026
• 38th Annual Healthcare Conference: 12/01/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:FATE
• CIK: 1434316
• Web: www.fatetherapeutics.com
• Phone: (858) 875-1800
• Fax: N/A
• Employees: 161
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Fate Therapeutics: $5.80
• High Price Target: $8.00
• Low Price Target: $3.00
• Potential Upside/Downside: +216.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$136.32 million
• Net Margins: -1,941.09%
• Pretax Margin: -1,941.09%
• Return on Equity: -65.08%
• Return on Assets: -41.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.85
• Quick Ratio: 4.85

Sales & Book Value

• Annual Sales: $6.65 million
• Price / Sales: 33.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.80 per share
• Price / Book: 1.02

Miscellaneous

• Outstanding Shares: 119,820,000
• Free Float: 114,141,000
• Market Cap: $219.87 million
• Optionable: Optionable
• Beta: 2.65